

1
2
3
4 **EFFECTS OF FEEDING ON THE PLASMA DISPOSITION KINETICS OF THE**
5 **ANTHELMINTIC ALBENDAZOLE IN LAYING HENS**

6
7 MARIANA BISTOLETTI, LUIS ALVAREZ, CARLOS LANUSSE & LAURA MORENO*

8
9
10 Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN),
11 CONICET, Facultad de Ciencias Veterinarias, UNCPBA, Tandil, Argentina.

12
13
14
15
16
17 **Corresponding author:* Dra. Laura Moreno Torrejón, Laboratorio de Farmacología, Centro de
18 Investigación Veterinaria de Tandil (CIVETAN), CONICET; Facultad de Ciencias
19 Veterinarias, UNCPBA, Campus Universitario, 7000, Tandil, ARGENTINA. Phone: +54-249-
20 4439850. Fax: +54-249-4439850. *E-mail address:* lmoreno@vet.unicen.edu.ar

21
22 **SHORT TITLE:** Albendazole pharmacokinetics in laying hens

23
24 **KEYWORDS:** albendazole; laying hen; pharmacokinetics; fasting effect; diet effect.

25

26

27 **ABSTRACT**

28 1.To optimize the potential use of ABZ as an anthelmintic in poultry, the effects of
29 different feed correlated factors (fasting and type of diet) on the plasma disposition kinetics of
30 ABZ and its metabolites in laying hens were evaluated.

31 2.Experiment-I: Twelve hens were distributed into two groups: Fed-group, hens fed *ad*
32 *libitum* with commercial food were orally treated with ABZ (10 mg/kg); Fasted-group,
33 animals receiving the same food were fasted over a 12 h period before ABZ treatment.

34 3.Experiment-II: Twelve hens were distributed into two groups: Pelleted-group, hens
35 fed *ad libitum* with pelleted commercial food were orally treated with ABZ (10 mg/kg);
36 Grain-group, hens fed *ad libitum* with a diet based in grains (wheat, corn) received the same
37 treatment.

38 4.Blood samples were taken at different times post-treatment and plasma analysed by
39 HPLC. ABZ and its metabolites ABZSO and ABZSO₂ were recovered in plasma after the oral
40 administration in all the groups.

41 5.The 12 h fasting period did not modify the disposition kinetics of ABZ, ABZSO and
42 ABZSO₂ in hens. In both groups ABZSO was measured in plasma up to 24 h post-treatment
43 with similar C_{max} and T_{max} values.

44 6.The type of feed affected ABZ kinetics. The mean ABZSO concentration profile were
45 higher and detected longer in the hens fed on grain compared to the fed on pelleted ration.
46 Although higher metabolite concentration profile was measured in the Grain-group, the AUC₀₋
47 _∞ values did not reach statistical differences between groups. Meanwhile, other
48 pharmacokinetic parameters (T_{1/2for} and T_{1/2el}) demonstrated the influence of diet on ABZ
49 disposition.

50 7.Those feeding related factors affecting ABZ kinetic behaviour should be considered
51 to optimise its use in parasite control in poultry. The knowledge on drug kinetic behaviour is

52 crucial to ensure the adequate and sustainable use of the limited available anthelmintic
53 therapeutic tools in avian parasite control.

54

55 **INTRODUCTION**

56 Aviary and deep-litter systems with or without access to a free-range area are
57 increasingly used in European egg production units. This production system has the advantage
58 to promote natural behaviour and increase animal welfare with the inconvenient that a
59 increased exposure to helminth parasites with a fecal–oral route of transmission has been
60 reported (Papini and Cacciuttolo, 2008; Jansson *et al.* 2010; Höglund and Jansson, 2011;
61 Kaufmann *et al.* 2011) Among the poultry helminths, *Ascaridia galli* and *Heterakis*
62 *gallinarum* are the most common species (Permin *et al.* 1999). They can cause weight
63 depression (Kilpinen *et al.* 2005) and damage the intestinal mucosa, sometimes leading to
64 haemorrhages, anaemia and severe diarrhoea. Heavy *A. galli* infections can obstruct the small
65 intestine and cause death (Ramadan and Znada, 1991) of affected animals. Although quite a
66 large number of organic layer farmers used homeopathic, phytotherapeutic or other alternative
67 medicines, the use of chemotherapeutics is currently inevitable to prevent animal suffering or
68 distress in organic husbandry (Van Der Meulen *et al.* 2007). However, the current situation is
69 similar to that of more than a decade ago (Ruff, 1999) with very few drugs available for
70 treatment of poultry helminth infections because the size of the market and severity of the
71 problem does not justify the escalating cost of developing and obtaining regulatory approval
72 for a new drug.

73 The benzimidazoles (BZD) are anthelmintic drugs (albendazole (ABZ), fenbendazole
74 (FBZ), flubendazole (FLBZ), triclabendazole (TCBZ), etc.) widely used in veterinary and
75 human medicine, being FLBZ the only BZD registered for poultry in many countries around
76 the world (EMEA, 2006).

77 The characterisation of the BZD plasma disposition kinetics can be used to predict its
78 anthelmintic efficacy. In fact, there is a direct relation between the concentration profiles of
79 BZD compounds measured in the bloodstream and those recovered within target parasites
80 (Alvarez *et al.* 1999; Alvarez *et al.* 2000), as well as BZD systemic exposure and clinical
81 efficacy (Hennessy *et al.* 1995; Moreno *et al.* 2004; Entrocasso *et al.* 2008; Alvarez *et al.*
82 2012; Barrère *et al.* 2012). The knowledge of the pharmacokinetic and metabolic patterns of
83 BZD anthelmintic in the different mammalian species as ruminant (Lanusse and Prichard,
84 1993a), dogs (McKellar *et al.* 1993; Sánchez *et al.* 2000), pigs (Alvarez *et al.* 1996) and
85 human (Edwards and Breckenridge, 1988) has been widely studied. However, the available
86 information on the kinetics of these compounds in avian species is scarce (Csiko *et al.* 1996;
87 De Ruyck *et al.* 2001). Since the anthelmintic efficacy of ABZ has been demonstrated in
88 chickens (Tucker *et al.* 2007), and there are several evidences that ABZ is being extra-
89 labelled used in avian production, we recently studied the plasma disposition kinetics of ABZ
90 in laying hens (Bistoletti *et al.* 2013).

91 It has been demonstrated that several host-related factors may affect the
92 pharmacokinetics and the resultant clinical efficacy of BZD compounds in different
93 mammalian species. The gastrointestinal digesta passage rate is affected by alteration in the
94 quality and quantity of the feed consumed, which confers variable absorption time affecting
95 bioavailability of orally administered BZD anthelmintics (Lifschitz *et al.* 1997; Sánchez *et al.*
96 1999; McKellar *et al.* 2002; Gokbulut *et al.* 2010).

97 The gastrointestinal anatomy and physiology in birds differs significantly from
98 mammalian species. Unlike mammals, the avian have no teeth in the buccal cavity (no
99 grinding); there is no sharp distinction between the pharynx and mouth (oropharynx). Salivary
100 glands are well developed in poultry and the oesophagus is expanded to form a crop. This

101 may influence the pharmacokinetic processes of most drugs, mainly when oral therapy
102 accounts for more than 90% of total drug administration in poultry (Vermeulen *et al.* 2002).

103 To improve the efficacy and safety of BZD anthelmintics, it is necessary to
104 characterize all the factors that may affect their pharmacokinetics. The knowledge of the
105 differences on drug behaviour and drug efficacy among animal species and the identification
106 of other factors affecting drug biotransformation pathways are relevant to achieve the optimal
107 parasite control and to limit the selection of drug-resistant parasites (Křížová-Forstová *et al.*
108 2011). To optimize the potential use of ABZ in poultry to a better parasite control, the aim of
109 the current study was to evaluate the effects of feeding related factors (fasting and diet
110 composition) on the plasma disposition kinetics of ABZ and its metabolites, the active
111 albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO₂), after oral
112 administration to laying hens.

113

114 **MATERIALS AND METHODS**

115 **Animals**

116 A total of twenty four (24) six month old *Plymouth* Rock Barrada laying hens with an average
117 body weight of 2.2 ± 0.3 kg were used in the current experimental work. Animals were
118 monitored daily for 2 weeks during acclimatization period, in which no clinical sign of
119 disease were observed. The hens were under uniform conditions of housing and feeding,
120 according to their specific requirements, with water and feed available *ad libitum*. Before the
121 experiments the hens had not been medicated with any antiparasitic drug. Animal procedures
122 and management protocols were approved by the Animal Welfare Policy (act 087/02) of the
123 faculty of Veterinary Medicine, Universidad Nacional del Centro de la Provincia de Buenos
124 Aires (UNCPBA), Tandil, Argentina ([http:// www.vet.unicen.edu.ar](http://www.vet.unicen.edu.ar)).

125

126 **Drug formulation**

127 Drug formulations used in the experiment were prepared in our laboratory. The ABZ 2%
128 suspension used for single oral administration was prepared weighting carefully 0.5 g of pure
129 ABZ standard and adding 25 ml of HPLC water and 0.125 g of carboxymethylcellulose.

130 **Experimental design, treatments and sampling**

131 *Experiment I: effect of fasting*

132 Twelve (12) hens were randomly distributed into two (2) groups of six (6) animals each as
133 follow: Fed group, hens fed *ad libitum* with balanced commercial food were treated with ABZ
134 (10 mg/kg, 2 % suspension) by the oral route through a 25-cm length plastic cannula; Fasted
135 group, hens were fasted over 12 h before to the ABZ treatment, which was performed as
136 previously described for the Fed group.

137 *Experiment II: effect of diet composition*

138 Twelve (12) hens were randomly distributed into two (2) groups of six (6) animals each as
139 follow: Pelleted group, hens were fed *ad libitum* with pelleted commercial food and treated
140 with ABZ (10 mg/kg, 2 % suspension) by the oral route through a 25-cm length plastic
141 cannula; Grain group, hens were fed *ad libitum* with a diet based in crushed grains (wheat and
142 corn) and treated with ABZ as previously described for the Group pelleted.

143 After drug administration (both experiments), blood samples (1 ml) were taken by an
144 intravenous catheter previously placed into the left wing vein at 1, 2, 3, 6, 9, 12, 15, 24, 30
145 and 48 h post-treatment. The volume of blood taken in each sample was replaced by the i.v.
146 infusion (1 ml) of sterile physiological saline solution. Blood samples collected in heparinized
147 tubes were centrifuged at 2000 \times g for 10 min, and the supernatant plasma collected was
148 frozen at -20 °C to be later analysed by high performance liquid chromatography (HPLC).

149

150

151 **Reagents and Chemicals**

152 Pure reference standards (97-99% purity) of ABZ and its metabolites, ABZSO, ABZSO₂ and
153 the internal standard (IS) oxibendazole (OBZ) were provided by Toronto Research Chemicals
154 Inc. (Toronto, Canada). Acetonitrile solvent used for the extraction and drug analysis were
155 HPLC grade and purchased from Sintorgan[®] S.A. (Buenos Aires, Argentina). Ammonium
156 acetate (HPLC grade) was from Baker (Phillipsburg, USA). Water was double distilled and
157 deionized using a water purification system (Simplicity[®] Millipore, São Paulo, Brazil).

158 **Plasma sample analysis**

159 Following the methodology previously described, plasma samples (0.5 ml) were extracted in
160 order to ABZ/metabolites quantification. Plasma samples were analysed using a HPLC
161 method previously validated (Bistoletti *et al.* 2011). The analytical method was developed
162 using a Shimadzu Chromatography system (Shimadzu Corporation, Kyoto, Japan). The
163 equipment was composed for two LC-10AS solvent pumps, an automatic sample injector (SIL-
164 10A), an ultraviolet visible spectrophotometric detector (UV) (SPD-10A), a column oven
165 (Eppendorf TC-45. Eppendorf, Madison, WI, USA) set at 35°C, and a CBM-10A data integrator.
166 Data and chromatograms were collected and analysed using the Class LC10 software (SPD-10A.
167 Shimadzu Corporation. Kyoto. Japan). A C₁₈ reversed-phase column (Kromasil[®] Eka Chemicals
168 AB, NY, USA) of 250 x 4.6 mm with 5 µm particle size was used for analyte separation. The
169 detection of drugs/metabolites was done at a wavelength of 292 nm. The calibration curves
170 for each analyte were constructed by least squares linear regression analysis, showed good
171 linearity with correlation coefficients greater than 0.9964. The absolute recoveries for ABZ,
172 ABZSO and ABZSO₂ ranged between 81.8 and 98.2%. Precision (intra- and inter- assay)
173 (CV) was lower than 7.79%. The limits of quantification (LOQ) for ABZ and its metabolites
174 ranged between 0.05 and 0.125 µg/µl.

175

176 **Pharmacokinetic analysis**

177 The pharmacokinetic analysis of the plasma concentration vs. time curves for ABZ and its
 178 metabolites for each animal was carried out using the PKsolution 2.0 software (Summit Research
 179 Services, Ashland, USA). The following equation was used to describe the biexponential plasma
 180 concentration-time curves for ABZSO and ABZSO₂ obtained after the oral administration of
 181 ABZ (Notari, 1987):

$$182 \quad C_p = Be^{-\beta t} - Be^{-Kt}$$

183 where C_p = concentration at time t after administration ($\mu\text{g}\cdot\text{ml}^{-1}$); B = concentration at
 184 time zero extrapolated from the elimination phase ($\mu\text{g}\cdot\text{ml}^{-1}$); e = base of the natural logarithm;
 185 β = terminal slope (h^{-1}) and K is the rapid slope obtained by feathering which represents the first
 186 order metabolite formation rate constant (K_{for}) (h^{-1}). The elimination half-life ($T_{1/2\text{el}}$) was
 187 calculated as $\ln 2/\beta$. The peak concentration (C_{max}) and time to peak concentration (T_{max}) were
 188 read from the plotted concentration-time curve for each analyte. The area under the
 189 concentration-time curve for ABZ/metabolites in plasma fluid was calculated by the trapezoidal
 190 rule (Gibaldi and Perrier, 1982) and further extrapolated to infinity ($\text{AUC}_{0-\infty}$) by dividing the last
 191 experimental concentration by the terminal slope (β). Statistical moment theory was applied to
 192 calculate the mean residence time (MRT) for ABZ and metabolites in plasma as follows (Gibaldi
 193 and Perrier, 1982).

$$194 \quad \text{MRT} = \text{AUMC}/\text{AUC}$$

195 Where AUC is defined previously and AUMC is the area under the curve of the product
 196 of time and the plasma drug concentration vs. time from 0 to ∞ (Gibaldi and Perrier, 1982).

197 **Statistical analysis of the data**

198 The pharmacokinetic parameters and concentration data are reported as mean \pm SEM. The time-
 199 based parameters (MRT, $T_{1/2\text{for}}$, $T_{1/2\text{el}}$) are expressed as harmonic means. Student t and Mann-

200 Whitney Test were used to compare parameters between groups. A value of $P < 0.05$ was
201 considered statistically significant.

202

203 **RESULTS**

204 **Effect of fasting**

205 ABZ parent drug and their ABZSO and ABZSO₂ metabolites were detected in plasma after the
206 oral administration of ABZ in fed and fasted groups. The comparative ABZ, ABZSO and
207 ABZSO₂ plasma profiles obtained for both groups are shown in Figure 1. The 12 h fasting
208 period did not modify the overall plasma drug disposition of ABZ/metabolites, resulting in
209 similar ($P > 0.05$) pharmacokinetic parameters obtained in fed and fasted animals. The plasma
210 pharmacokinetic parameters calculated for ABZSO and ABZSO₂ in fed and fasted groups are
211 presented in Table 1. The low ABZ concentrations detected during a short time period precluded
212 the development of a complete pharmacokinetic analysis of the data obtained for this molecule
213 after its oral administration. The statistical comparison between groups did not show differences
214 in any case. In both experimental groups the ABZ C_{max} was reached at 2 h, with values ranging
215 from 0.11 and 0.21 $\mu\text{g/ml}$ for fed and fasted groups, respectively. ABZ parent drug was rapidly
216 biotransformed to ABZSO and ABZSO₂. In both groups, ABZSO was measured in plasma till
217 24 h post-treatment with similar C_{max} and T_{max} values. ABZSO₂ plasma drug exposure was lower
218 compared to that observed for ABZSO, being quantified in plasma from 2 to 30 h post-treatment.
219 The ABZSO₂ metabolite reached the C_{max} (0.47 $\mu\text{g/ml}$) at 8 h (T_{max}) post-treatment in fed
220 animals, values which resulted similar in fasted hens ($C_{max} = 0.42 \mu\text{g/ml}$; $T_{max} = 9 \text{ h}$).

221 **Effect of diet composition**

222 The mean plasma concentration profiles for ABZ and its metabolites after its oral
223 administration at 10 mg/kg to hens fed with pelleted commercial balanced (Pelleted group) or
224 crushed grains (Grain group) diets are shown in Figure 2. Table 2 summarises the plasma

225 pharmacokinetic parameters for ABZSO and ABZSO₂ obtained after the oral administration
226 of ABZ to hens from Pelleted or Grain groups. The type of feed affected ABZ kinetics. Both
227 ABZ and metabolites mean concentration were higher and detected longer in the Grain group
228 compared to that observed in the Pelleted group. Once again, the scarce ABZ concentration
229 quantified in plasma precluded a complete pharmacokinetic study. There was a general
230 upward trend in the plasma concentration profiles of ABZSO in the Grain group. In fact, an
231 increment of ABZSO AUC (64%) was observed in hens fed with grain compared to that
232 obtained in the Pelleted group. However, the high variability in these concentrations at the
233 different sampling times did not permit to obtain statistically significant differences between
234 groups. Meanwhile, statistical differences for $T_{1/2el}$ and $T_{1/2for}$ for ABZSO, and $T_{1/2el}$ and MRT
235 for ABZSO₂ between groups, demonstrated the influence of diet on ABZ disposition.

236

237 **DISCUSSION**

238 New tendencies in animal production regarding the sustainability and welfare has led to the
239 ban of the conventional cages for laying hens in Germany since 2010 and the European Union
240 after 2012 (1999/74/EC, Anonymous, 1999). In accordance with this legislation, a
241 progressively increasing number of farmers have adopted breeding programs on soil; as a
242 consequence, a high prevalence of helminth infections has been reported. In Germany, almost
243 all hens (99.6%, N=737) harboured at least one helminth species. The most prevalent species
244 were the nematodes *Heterakis gallinarum* (98%) followed by *Ascaridia galli* (88%) and
245 *Capillaria* spp. (75.3%). The overall prevalence of the cestodes was 24.9%. The vast majority
246 of the hens are subclinically infected with helminth species. The results indicate that it is
247 essential to adopt alternative control strategies in order to lower infection risks in organic
248 production systems which are gaining popularity (Kaufmann *et al.* 2011). Although quite a
249 large number of organic layer farmers used homeopathic, phytotherapeutic, or other

250 alternative medicines, the use of chemotherapeutics is currently inevitable to prevent animal
251 suffering or distress in organic husbandry (Van Der Meulen *et al.* 2007).

252 The close relationship between pharmacokinetics and clinical efficacy for anthelmintic
253 compounds has been well documented. The characterization of the plasma disposition kinetics
254 of anthelmintics (parent drug and/or its metabolites) can be used to predict and optimize its
255 antiparasitic efficacy (Lanusse and Prichard, 1993a).

256 We recently studied the plasma disposition kinetics of ABZ in laying hens (Bistoletti *et al.*
257 2013) to know the pharmacokinetic behavior of ABZ in this species as the first step to
258 evaluate its potential as an anthelmintic tool for use in this species. In order to optimize its use
259 to a better parasite control, in the current study the effect of different feed related factors, such
260 as fasting and diet composition, on the plasma disposition kinetics of ABZ and its metabolites
261 were assessed for the first time after oral administration to laying hens.

262 The limited water solubility of BZD anthelmintics allows them to be formulated only
263 as suspensions, pastes or granules for oral administration. In these experiments ABZ was
264 administered to the hens as a micronized suspension. The dissolution of the drug particles is a
265 crucial step that precedes the gastrointestinal absorption of a drug formulated as a suspension.
266 The aqueous solubility of ABZ is markedly higher at low pH values (McKellar and Scott,
267 1990). Different factors affecting the plasma disposition kinetics of BZD anthelmintics, may
268 affect the time over which the parasites are exposed to toxic concentrations. It has been
269 reported that feeding restriction significantly modifies the plasma disposition kinetics of ABZ
270 and its metabolites in different mammalian species (Singh *et al.* 1999; Sánchez *et al.* 2000;
271 Gokbulut *et al.* 2010). In the present work we evaluated the effect of 12 h fasting period on
272 ABZ plasma disposition after oral administration to laying hens. Unlike observations what
273 happens in other animal species, fasting pre-treatment did not induced marked changes in the
274 ABZ/metabolites plasma drug exposure in laying hen. ABZSO and ABZSO₂ plasma exposure

275 (expressed as $AUC_{0-\infty}$) did not differ between hens fasted before treatment compared to those
276 obtained in control (unfasted) animals, indicating that the 12 h fasting period was not enough
277 to significantly modify the plasma disposition kinetics of ABZ/metabolites in hens.

278 On the other hand, numerous studies have reported the way in which the type of diet
279 affects the kinetics of the different BZD anthelmintic drugs in mammalian species (Alvarez *et*
280 *al.* 1996; Knox and Steel, 1997; Virkel *et al.* 1999; Gokbulut *et al.* 2007). Different feeds may
281 induce changes in pH and microbial population at intestinal level. Consequently, drug
282 biotransformation and absorption through biological membranes could be modified. The
283 accumulated data appears to indicate that the effect of diet composition on the
284 pharmacokinetics of BZD anthelmintics differs between monogastric and ruminants species.
285 Some effects of diet composition on ABZ pharmacokinetics in hens were observed in the
286 current study. The observed effect, mainly focused in the rate of absorption/formation of
287 ABZ/ABZSO, could be related with changes on gastrointestinal anatomy/structure induced by
288 the food. It has been reported that consumption of diets with different characteristics may
289 have a direct effect on the morphological structure of the digestive system of the birds, such
290 that any alteration in the structure of the feed might have a significant effect on performance
291 by restricting or making some nutrients and/or drugs unavailable (Macari *et al.* 1994). For
292 example, birds that eat fiber and/or coarse food tend to have a longer gastrointestinal tract
293 (Denbow, 2000). On the other hand, both gizzard atrophy (Nir *et al.* 1994a; Nir *et al.* 1995)
294 and a discrete intestinal hypertrophy (Nir *et al.* 1994a) have been observed when finely
295 ground food was fed to the birds. In the current experiment, we compare ABZ
296 pharmacokinetics in hens fed with cereals (wheat and corn) or pelleted food and differences
297 were found between groups. ABZ and metabolite concentrations were higher in grain fed hens
298 than in pelleting fed group. However, these differences were not as evident as observed in
299 ruminants, since statistical differences were not found for C_{max} and $AUC_{0-\infty}$, probably due to

300 the high variability of the data, which has been associated with the eating habits of the hens
301 (Bistoletti *et al.* 2013). Interestingly, while in other animal species such as pigs (Alvarez *et al.*
302 1996), dogs (Sánchez *et al.* 2001) and ruminants (Prichard *et al.* 1985; Hennessy *et al.* 1993)
303 ABZ is not detected in plasma after its enteral administration, the parent drug was quantified
304 in hens. This finding has been previously associated to a fast absorption process and/or a slow
305 metabolic rate in hens compared with other species (Csiko *et al.* 1996; Bistoletti *et al.* 2013).
306 Additionally, the irrigation of the hen gastrointestinal tract may help to explain the obtained
307 result. While drug absorbed at proventriculus, gizzard or intestines reach the liver drained by
308 the venous portal system, drug absorbed at the crop reach the systemic circulation through the
309 jugular vein (Sisson & Grossman, 1982) avoiding the liver “first pass” effect.

310 Gastrointestinal absorption of ABZ is limited by its poor water solubility, which is
311 markedly improved at low pH values. While in ruminants the abomasum play an important
312 role in ABZ dissolution, in avian species this function is associated to the gizzard (muscular
313 stomach), which is a powerful triturating machine with low physiological pH (between 2-3.5)
314 (Vermeulen *et al.* 2002). When hens were fed with different diets based in grains or pellets,
315 the ABZ dissolution and absorption processes may have been different. It has been
316 demonstrated that ingredients with larger particle size have lower rate of passage through the
317 gastrointestinal tract (Amerah *et al.* 2007), which results in a greater contact between the
318 food/gastrointestinal content and the intestinal mucosa. In addition to this, pelleting also
319 seems to directly affect the gastrointestinal tract structure. Nir *et al.* (1995) observed that
320 pelleting resulted in a decrease in the weight and contents of the proventriculus, gizzard and
321 small intestine, as well as a decrease in the small intestine length, without changing the pH of
322 these segments (Nir *et al.* 1994a; Nir *et al.* 1995). Considering these aspects, hens fed with
323 corn or wheel grains need longer digestion time compared to that fed with pellets. The
324 extended time for grinding cereal grains in the gizzard, produced a greater decrease of pH

325 value, thus promoting a better and longer dissolution process of ABZ particles and the
326 subsequent higher absorption of the drug from the gut, explaining the higher plasma
327 concentrations (ABZ/metabolites), longer $T_{1/2for}$ (related to a delayed ABZ absorption) and
328 $T_{1/2el}$ for both ABZSO (active) and ABZSO₂ metabolites in the Grain group. Meanwhile, since
329 the pellet dissolves within the proventriculus (Nir *et al.* 1994b), the digestion time in the
330 gizzard and contact of food/drug with the acidic media is shorter than that for grain diet,
331 explaining the lower ABZ/metabolites plasma disposition and shorter $T_{1/2for}$ and $T_{1/2el}$ found
332 for this group.

333 In conclusion, different factors affecting the ABZ plasma pharmacokinetics in laying
334 hens were evaluated. A 12 h fasting period did not produce any effect on ABZ disposition in
335 laying hens. The type of feed affected the peak plasma concentrations of ABZ and its
336 metabolites and their persistence on the blood stream, which may be related to a better
337 dissolution and gastro-intestinal absorption of ABZ in grain fed hens. Overall, those feeding
338 related factors affecting ABZ kinetic behaviour should be considered to optimise its use in
339 parasite control in poultry. The knowledge on drug kinetic behaviour is crucial to ensure the
340 adequate and sustainable use of the limited available anthelmintic therapeutic tools in avian
341 parasite control.

342

343 **ACKNOWLEDGMENTS**

344 Mariana Bistoletti is a recipient of a Doctoral Fellowship from the Consejo Nacional de
345 Investigaciones Científicas y Técnicas (CONICET), Argentina. The experimental animals and
346 facilities provided by “Unidad Académica Dr. Ramón Santamarina, Escuela de Educación
347 Agropecuaria N°1” (Tandil Argentina), is acknowledged. This research was financially
348 supported by CONICET (PIP N 112 200801 02184).

349

350 **REFERENCES**

351

352 ALVAREZ, L., IMPERIALE, F., SÁNCHEZ, S., MURNO, G., LANUSSE, C. (2000) Uptake
353 of albendazole and albendazole sulphoxide by *Haemonchus contortus* and *Fasciola*
354 *hepatica* in sheep. *Veterinary Parasitology*, **94** : 75-89.

355 ALVAREZ, L., SÁNCHEZ, S. & LANUSSE, C. (1999) *In vivo* and *ex vivo* uptake of
356 albendazole and its sulphoxide metabolite by cestode parasites: relationship with their
357 kinetic behaviour in sheep. *Journal of Veterinary Pharmacology and Therapeutics* , **22** :
358 77-86.

359 ALVAREZ, L., SAUMELL, C., SÁNCHEZ, S. & LANUSSE, C. (1996) Plasma disposition
360 kinetics of albendazole metabolites in pigs fed different diets. *Research in Veterinary*
361 *Science*, **60** : 152-156.

362 ALVAREZ, L., SUAREZ, G., CEBALLOS, L., MORENO, L. & LANUSSE, C. (2012)
363 Dose-dependent systemic exposure of albendazole metabolites in lambs. *Journal of*
364 *Veterinary Pharmacology and Therapeutics*, **35** : 365-372.

365 AMERAH, A. M., RAVINDRAN, V., LENTLE, R. G. & THOMAS, D. G. (2007) Feed
366 particle size: implications on the digestion and performance of poultry. *World's Poultry*
367 *Science Journal*, **63** : 439-455.

368 ANONYMOUS, (1999) Official Journal of the European Communities. COUNCIL
369 DIRECTIVE 1999/74/EC laying down minimum standards for the protection of laying
370 hens. Off. J. Eur. Commun. L 203, 53.

371 BARRÈRE, V., ALVAREZ, L., SUAREZ, G., CEBALLOS, L., MORENO, L., LANUSSE,
372 C. & PRICHARD, R. (2012) Relationship between increased albendazole systemic
373 exposure and changes in single nucleotide polymorphisms on the beta-tubulin isotype 1
374 encoding gene in *Haemonchus contortus*. *Veterinary Parasitology*, **186** : 344-349.

- 375 BISTOLETTI, M., MORENO, L., ALVAREZ, L. & LANUSSE, C. (2011) Multiresidue
376 HPLC method to measure benzimidazole anthelmintics in plasma and egg from laying
377 hens. Evaluation of albendazole metabolites residues profiles. *Food chemistry* , **126** : 793-
378 800.
- 379 BISTOLETTI, M., ALVAREZ, L., LANUSSE, C. & MORENO, L. (2013) Disposition
380 kinetics of albendazole and metabolites in laying hens. *Journal of Veterinary*
381 *Pharmacology and Therapeutics*, **36** : 161-168.
- 382 CSIKO, G.Y., BANHIDI, G.Y., SEMJEN, G., LACZAY, P., VANYINE SANDOR, G.,
383 LEHEL, J. & FEKETE, J. (1996) Metabolism and pharmacokinetics of albendazole after
384 oral administration to chickens. *Journal of Veterinary Pharmacology and Therapeutics* ,
385 **19** : 322-325.
- 386 DENBOW, D.M. (2000) Gastrointestinal anatomy and physiology, in: WHITTOW, G.C. (Ed)
387 *Sturkie's Avian Physiology* , pp. 299-325 (London, Academic Press).
- 388 DE RUYCK, H., DAESELEIRE, E., GRIJSPEERDT, K., DE RIDDER, G., VAN
389 RENTERGHEM, R. & HUYGHEBAERT, G. (2001) Determination of flubendazole and
390 its metabolites in eggs and poultry muscle with liquid chromatography– tandem mass
391 spectrometry. *Journal of Agricultural Food Chemistry*, **49**, 610–617.
- 392 EMEA/CVMP/33128/2006-FINAL (2006). Flubendazole (Extrapolation to poultry).
393 Summary report (4). Available from:
394 [http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits -](http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014292.pdf)
395 [_Report/2009/11/WC500014292.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014292.pdf)
- 396 ENTROCASSO, C., ALVAREZ, L., MANAZZA, J., LIFSCHITZ, A., BORDA, B.,
397 VIRKEL, G., MOTTIER, L. & LANUSSE, C. (2008) Clinical efficacy assessment of the
398 albendazole-ivermectin combination in lambs parasitized with resistant nematodes.
399 *Veterinary Parasitology*, **155** : 249-256.

- 400 EDWARDS, G. & BRECKENRIDGE, AM. (1988) Clinical pharmacokinetics of anthelmintic
401 drugs. *Clinical Pharmacokinetics*, **15** :67-93.
- 402 GIBALDI, M. & PERRIER, D. (1982) *Pharmacokinetics*. 2nd edn. Revised and Expanded,
403 pp. 45 (New York, Marcel Dekker, Inc).
- 404 GOKBULUT, C., BOYACIOGLU, M., KARADEMIR, U., AKSIT, D. (2010) The effect of
405 fasting on the plasma disposition of triclabendazole following oral administration in goats.
406 *Research in Veterinary Science* , **89** : 415–417.
- 407 GOKBULUT, C., KARADEMIR, U., BOYACIOGLU, M. & AKAR, F. (2007) The effect of
408 diet type on the plasma disposition of triclabendazole in goats. *Research in Veterinary*
409 *Science* , **82** : 388–391.
- 410 HENNESSY, D.R., ALI, D. & SILLINCE, J. (1995) The effect of a short-term reduction in
411 feed on the pharmacokinetics and efficacy of albendazole in sheep. *Australian Veterinary*
412 *Journal* **12** : 29-30.
- 413 HENNESSY, D.R., SANGSTER, N.C., STEEL, J.W., & COLLINS, G.H. (1993)
414 Comparative pharmacokinetic behaviour of albendazole in sheep and goats. *International*
415 *Journal for Parasitology* , **23** : 321-325.
- 416 HÖGLUND, J. & JANSSON, D.S. (2011) Infection dynamics of *Ascaridia galli* in non-caged
417 laying hens. *Veterinary Parasitology* , **180** : 267-273.
- 418 JANSSON, D.S., NYMAN, A., VÅGSHOLM, I., CHRISTENSSON, D., GÖRANSSON, M.,
419 FOSSUM, O. & HÖGLUND, J. (2010) Ascarid infections in laying hens kept in different
420 housing systems. *Avian Pathology* , **39** : 525-532.
- 421 KAUFMANN, F., DAŞ, G., SOHNREY, B. & GAULY, M. (2011) Helminth infections in
422 laying hens kept in organic free range system in Germany. *Livestock Science* , **141** : 182-
423 184.

- 424 KILPINEN, O., ROEPSTORFF, A., PERMIN, A., NORGAARD-NIELSEN, G., LAWSSON,
425 L.G. & SIMONSEN, H.B. (2005) Influence of *Dermanyssus gallinae* and *Ascaridia galli*
426 infections on behaviour and health of laying hens (*Gallus gallus domesticus*). *British*
427 *Poultry Science* , **46** : 26–34.
- 428 KNOX, M.R. & STEEL, J.W. (1997) Effect of diet and species on the pharmacokinetic of
429 fenbendazole in cattle. *Veterinary Research Communications* , **21** : 37–43.
- 430 KŘÍŽOVÁ-FORSTOVÁ, V., LAMKA, J., CVILINK, V., HANUŠOVA, V. & SKÁLOVÁ,
431 L. (2011) Factors affecting pharmacokinetics of benzimidazole anthelmintics in food-
432 producing animals: The consequences and potential risks. . *Research in Veterinary Science*
433 **91** : 333–341.
- 434 LANUSSE, C. & PRICHARD, R. (1993a). Relationship between pharmacological properties
435 and clinical efficacy of ruminant anthelmintics. *Veterinary Parasitology* , **49** : 123–158.
- 436 LANUSSE, C. & PRICHARD, R. (1993b). Clinical pharmacokinetics and metabolism of
437 BZD anthelmintics in ruminant. *Drug Metabolism Reviews* , **25** : 235-279.
- 438 LIFSCHITZ, A., VIRKEL, G., MASTROMARINO, M. & LANUSSE, C. (1997) Enhanced
439 plasma availability of the metabolites of albendazole in fasted adult sheep. *Veterinary*
440 *Research Communications* , **21** : 201-211.
- 441 MACARI, M., FURLAN, R.L. & GONZALES, E. (1994) Fisiologia aviária aplicada a
442 frangos de corte. Jaboticabal: Funep/Unesp, 294.
- 443 MCKELLAR, Q. & SCOTT, E. (1990) The benzimidazole anthelmintic agents-a review.
444 *Journal of Veterinary Pharmacology and Therapeutics* , **13** : 223-247.
- 445 MCKELLAR, Q., GALBRAITH, E. & BAXTER, P. (1993) Oral absorption and
446 bioavailability of fenbendazole in the dog and the effect of concurrent ingestion of food.
447 *Journal of Veterinary Pharmacology and Therapeutics*, **16** : 189-198.

- 448 MCKELLAR, Q.A., GOKBULUT, C., MUZANDU, K. & BENCHAOUI, H. (2002)
449 Fenbendazole pharmacokinetics, metabolism, and potentiation in horses. *Drug Metabolism*
450 *and Disposition*, **30** : 1230-1239.
- 451 MORENO, L., ECHEVARRIA, F., MUÑOZ, F., ALVAREZ, L.I., SÁNCHEZ, S. &
452 LANUSSE; C. (2004) Dose-dependent activity of albendazole against benzimidazole-
453 resistant nematodes in sheep: relationship between pharmacokinetics and efficacy.
454 *Experimental Parasitology*, **106** : 150-157.
- 455 NIR, I., HILLEL, R. & PTICHI, I. (1995) Effect of particle size on performance: 3. Grinding
456 pelleting interactions. *Poultry Science* , **74** : 771-783.
- 457 NIR, I., SHEFET, Y. & ARONI, G. (1994a) Effect of particle size on performance. 1.Corn.
458 *Poultry Science* , **73** : 45-49.
- 459 NIR, I., TWINA, Y., GROSSMAN, E. & NITSAN, Z. (1994b) Quantitative effects of
460 pelleting on performance, gastrointestinal tract and behavior of meat-type chicken. *British*
461 *Poultry Science* , **35** : 589-602.
- 462 NOTARI, R. (1987) *Biopharmaceutics and Clinical Pharmacokinetics* , (New York, Marcel
463 Dekker).
- 464 PAPINI, R. & CACCIUTTOLO, E. (2008) Observations on the occurrence of *Heterakis*
465 *gallinarum* in laying hens kept on soil. *Italian Journal of Animal Science* , **7** : 487-493.
- 466 PERMIN, A., BISGAARD, M., FRANSEN, F., PEARMAN, M., NANSEN, P., KOLD, J.,
467 1999. The prevalence of gastrointestinal helminths in different poultry production systems.
468 *British Poultry Science*, **40** : 439–443.
- 469 PRICHARD, R., HENNESSY, D., STEEL, J. & LACEY, E. (1985) Metabolite
470 concentrations in plasma following treatment of cattle with five anthelmintics. *Research in*
471 *Veterinary Science* , **39** : 113-178.

- 472 RAMADAN, H.H. & ZNADA, A.N.Y. (1991) Some pathological and biochemical studies on
473 experimental ascariasis in chickens. *Nahrung* , **35** : 71–84.
- 474 RUFF, M.D. (1999) Important parasites in poultry production systems. *Veterinary*
475 *Parasitology* , **84** : 337-347.
- 476 SÁNCHEZ, S., ALVAREZ, L., PIS, A., QUIROGA, M. & LANUSSE, C. (1999) Differences
477 on the plasma and abomasal disposition of albendazole and its metabolites in calves
478 grazing on pasture or fed a concentrate diet. *Research in Veterinary Science*, **66** : 223-230.
- 479 SÁNCHEZ, S., SALLOVITZ, J., MCKELLAR, Q. & LANUSSE, C. (2000) Comparative
480 availability of two oral dosage forms of albendazole in dogs. *Veterinary Journal*, **160** :
481 153-156.
- 482 SINGH, D., SANYAL, P.K., SWARNKAR, C.P., KHAN, F.A. & BHAGWAN, P.S. (1999)
483 Influence of diet type and pretreatment fasting on the disposition kinetics of albendazole in
484 sheep. *Veterinary Research Communications*, **23** : 229–240.
- 485 SISSON, S. & GROSSMAN, J. (1982) Anatomía de los animales domésticos. 5ta. Edición,
486 Salvat Editores, Barcelona, pp. 2196.
- 487 TUCKER, C.A., YAZWINSKI, T.A., REYNOLDS, L., JOHNSON, Z. & KEATING, M.
488 (2007) Determination of the anthelmintic efficacy of albendazole in the treatment of
489 chickens naturally infected with gastrointestinal helminths. *Journal of Applied Poultry*
490 *Research* , **16** : 392-396.
- 491 VAN DER MEULEN, J., VAN DER WERF, J.T.N & KIJLSTRA, A. (2007) Questionnaire
492 survey of disease prevalence and veterinary treatments in organic layer husbandry in the
493 Netherlands. *TijdschriftvoorDiergeneeskunde* , **132** : 292-295.
- 494 VERMEULEN, B., DE BACKER, P., & REMON, J. P. (2002). Drug administration to
495 poultry. *Advanced Drug Delivery Reviews* , **54** : 795–803.

496 VIRKEL, G., LIFSCHITZ, A., PIS, A. & LANUSSE, C. (1999) Influence of diet on the
497 pattern of gastrointestinal biotransformation of netobimin and albendazole sulphoxide in
498 sheep. *European Journal of Drug Metabolism and Pharmacokinetics* , **24** : 31–37.

499

Figure legends

500

501

502 Figure 1. Mean (\pm SEM) albendazole (ABZ), albendazole sulphoxide (ABZSO) and
503 albendazole sulphone (ABZSO₂) plasma concentration profiles obtained after oral
504 administration of ABZ (10 mg/kg) to laying hens either fed *ad libitum* or fasted over 12 h
505 prior to treatment.

506

507

508 Figure 2. Mean (\pm SEM) albendazole (ABZ), albendazole sulphoxide (ABZSO) and
509 albendazole sulphone (ABZSO₂) plasma concentration profiles measured after oral
510 administration of ABZ (10 mg/kg) to laying hens either fed on grains based or pelleted diet.

511

512

513